- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Psoriatic arthritis Crohn disease Chronic plaque psoriasis Ulcerative colitis
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 570KB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 100KB)
Ustekinumab – March 2024
Ustekinumab: Injection 45 mg in 0.5 mL, Injection 45 mg in 0.5 mL single use pre filled syringe, Injection 90 mg in 1 mL single use pre filled syringe, Solution for I.V. infusion 130 mg in 26 mL; Wezlana®
Last updated
30 May 2025
